We are happy to introduce LSI Epsilons 9th investment Abarceo Pharma AB, a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).We look forward to work closely with Adam Bruce,...
LSI Epsilon invest in Abarceo Pharma
läs mer



